Cargando…
Obesity paradox in cardiovascular disease: where do we stand?
Obesity is associated with an increased risk of developing cardiovascular disease (CVD), particularly heart failure (HF) and coronary heart disease (CHD). The mechanisms through which obesity increases CVD risk involve changes in body composition that can affect hemodynamics and alters heart structu...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6503652/ https://www.ncbi.nlm.nih.gov/pubmed/31118651 http://dx.doi.org/10.2147/VHRM.S168946 |
_version_ | 1783416446438604800 |
---|---|
author | Carbone, Salvatore Canada, Justin M Billingsley, Hayley E Siddiqui, Mohammad S Elagizi, Andrew Lavie, Carl J |
author_facet | Carbone, Salvatore Canada, Justin M Billingsley, Hayley E Siddiqui, Mohammad S Elagizi, Andrew Lavie, Carl J |
author_sort | Carbone, Salvatore |
collection | PubMed |
description | Obesity is associated with an increased risk of developing cardiovascular disease (CVD), particularly heart failure (HF) and coronary heart disease (CHD). The mechanisms through which obesity increases CVD risk involve changes in body composition that can affect hemodynamics and alters heart structure. Pro-inflammatory cytokines produced by the adipose tissue itself which can induce cardiac dysfunction and can promote the formation of atherosclerotic plaques. When obesity and HF or CHD coexist, individuals with class I obesity present a more favorable prognosis compared to individuals who are normal or underweight. This phenomenon has been termed the “obesity paradox.” Obesity is defined as an excess fat mass (FM), but individuals with obesity typically also present with an increased amount of lean mass (LM). The increase in LM may explain part of the obesity paradox as it is associated with improved cardiorespiratory fitness (CRF), a major determinant of clinical outcomes in the general population, but particularly in those with CVD, including HF. While increased LM is a stronger prognosticator in HF compared to FM, in patients with CHD excess FM can exert protective effects particularly when not associated with increased systemic inflammation. In the present review, we discuss the mechanisms through which obesity may increase the risk for CVD, and how it may exert protective effects in the setting of established CVD, with a focus on body composition. We also highlight the importance of measuring or estimating CRF, including body composition-adjusted measures of CRF (ie, lean peak oxygen consumption) for an improved risk status stratification in patients with CVD and finally, we discuss the potential non-pharmacologic therapeutics, such as exercise training and dietary interventions, aimed at improving CRF and perhaps clinical outcomes. |
format | Online Article Text |
id | pubmed-6503652 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-65036522019-05-22 Obesity paradox in cardiovascular disease: where do we stand? Carbone, Salvatore Canada, Justin M Billingsley, Hayley E Siddiqui, Mohammad S Elagizi, Andrew Lavie, Carl J Vasc Health Risk Manag Review Obesity is associated with an increased risk of developing cardiovascular disease (CVD), particularly heart failure (HF) and coronary heart disease (CHD). The mechanisms through which obesity increases CVD risk involve changes in body composition that can affect hemodynamics and alters heart structure. Pro-inflammatory cytokines produced by the adipose tissue itself which can induce cardiac dysfunction and can promote the formation of atherosclerotic plaques. When obesity and HF or CHD coexist, individuals with class I obesity present a more favorable prognosis compared to individuals who are normal or underweight. This phenomenon has been termed the “obesity paradox.” Obesity is defined as an excess fat mass (FM), but individuals with obesity typically also present with an increased amount of lean mass (LM). The increase in LM may explain part of the obesity paradox as it is associated with improved cardiorespiratory fitness (CRF), a major determinant of clinical outcomes in the general population, but particularly in those with CVD, including HF. While increased LM is a stronger prognosticator in HF compared to FM, in patients with CHD excess FM can exert protective effects particularly when not associated with increased systemic inflammation. In the present review, we discuss the mechanisms through which obesity may increase the risk for CVD, and how it may exert protective effects in the setting of established CVD, with a focus on body composition. We also highlight the importance of measuring or estimating CRF, including body composition-adjusted measures of CRF (ie, lean peak oxygen consumption) for an improved risk status stratification in patients with CVD and finally, we discuss the potential non-pharmacologic therapeutics, such as exercise training and dietary interventions, aimed at improving CRF and perhaps clinical outcomes. Dove 2019-05-01 /pmc/articles/PMC6503652/ /pubmed/31118651 http://dx.doi.org/10.2147/VHRM.S168946 Text en © 2019 Carbone et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Review Carbone, Salvatore Canada, Justin M Billingsley, Hayley E Siddiqui, Mohammad S Elagizi, Andrew Lavie, Carl J Obesity paradox in cardiovascular disease: where do we stand? |
title | Obesity paradox in cardiovascular disease: where do we stand? |
title_full | Obesity paradox in cardiovascular disease: where do we stand? |
title_fullStr | Obesity paradox in cardiovascular disease: where do we stand? |
title_full_unstemmed | Obesity paradox in cardiovascular disease: where do we stand? |
title_short | Obesity paradox in cardiovascular disease: where do we stand? |
title_sort | obesity paradox in cardiovascular disease: where do we stand? |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6503652/ https://www.ncbi.nlm.nih.gov/pubmed/31118651 http://dx.doi.org/10.2147/VHRM.S168946 |
work_keys_str_mv | AT carbonesalvatore obesityparadoxincardiovasculardiseasewheredowestand AT canadajustinm obesityparadoxincardiovasculardiseasewheredowestand AT billingsleyhayleye obesityparadoxincardiovasculardiseasewheredowestand AT siddiquimohammads obesityparadoxincardiovasculardiseasewheredowestand AT elagiziandrew obesityparadoxincardiovasculardiseasewheredowestand AT laviecarlj obesityparadoxincardiovasculardiseasewheredowestand |